“Hypersomnia Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypersomnia Market.
The Hypersomnia Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hypersomnia Pipeline Report:
Companies across the globe are diligently working toward developing novel Hypersomnia treatment therapies with a considerable amount of success over the years.
Hypersomnia companies working in the treatment market are Avadel Pharmaceuticals, Zevra Therapeutics, Alkermes, and others, are developing therapies for the Hypersomnia treatment
Emerging Hypersomnia therapies in the different phases of clinical trials are- Lumryz, KP1077, ALKS 2680, and others are expected to have a significant impact on the Hypersomnia market in the coming years.
In November 2024, Axsome Therapeutics reported that its investigational narcolepsy treatment, AXS-12 (reboxetine), successfully met the primary endpoint in a Phase III ENCORE trial (NCT05059223). As a norepinephrine reuptake inhibitor and cortical dopamine modulator, AXS-12 demonstrated a 72% reduction in cataplexy attacks after one month and an 82% reduction at six months.
In September 2024, Alkermes plc (Nasdaq: ALKS) announced its plans to present clinical data from the Phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at the European Sleep Research Society (ESRS) conference, scheduled for September 24-27, 2024, in Seville, Spain. ALKS 2680 is an investigational, oral, selective orexin 2 receptor (OX2R) agonist being developed as a once-daily treatment for narcolepsy, a chronic neurological disorder marked by excessive daytime sleepiness
In September2024, Takeda (TSE:4502/NYSE:TAK) will present additional data from its Phase 2b trials (TAK-861-2001, TAK-861-2002) and the long-term extension (LTE) study (TAK-861-2003) evaluating TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), taking place from September 24-27, 2024, in Seville, Spain. TAK-861 is an investigational oral orexin receptor 2 (OX2R) selective agonist designed to address orexin deficiency in NT1 by specifically stimulating the orexin receptor 2. It has the potential to become the first treatment targeting the underlying pathophysiology of NT1.
In September 2024, Zevra Therapeutics, Inc. (NasdaqGS: ZVRA), a commercial-stage company specializing in rare disease therapeutics, announced that Rene Braeckman, Ph.D., Senior Vice President of Clinical Development, will present top-line results from the Phase 2 placebo-controlled, double-blind, randomized withdrawal clinical trial (NCT05668754) evaluating the safety and tolerability of KP1077 (serdexmethylphenidate, or SDX) in patients with idiopathic hypersomnia (IH). The data will be presented at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), in Seville.
Hypersomnia Overview
Hypersomnia is a sleep disorder characterized by excessive daytime sleepiness (EDS) despite getting adequate or prolonged sleep at night. Individuals with hypersomnia often struggle to stay awake during the day, leading to difficulties in work, school, and daily activities. The condition can be primary (idiopathic hypersomnia) or secondary to other medical conditions such as sleep apnea, narcolepsy, depression, or neurological disorders. Treatment typically involves lifestyle modifications, stimulant medications, or addressing underlying causes.
Get a Free Sample PDF Report to know more about Hypersomnia Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hypersomnia-pipeline-insight
Emerging Hypersomnia Drugs Under Different Phases of Clinical Development Include:
Lumryz: Avadel Pharmaceuticals
KP1077: Zevra Therapeutics
ALKS 2680: Alkermes
Hypersomnia Route of Administration
Hypersomnia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Hypersomnia Molecule Type
Hypersomnia Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Hypersomnia Pipeline Therapeutics Assessment
Hypersomnia Assessment by Product Type
Hypersomnia By Stage and Product Type
Hypersomnia Assessment by Route of Administration
Hypersomnia By Stage and Route of Administration
Hypersomnia Assessment by Molecule Type
Hypersomnia by Stage and Molecule Type
DelveInsight’s Hypersomnia Report covers around 10+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Hypersomnia product details are provided in the report. Download the Hypersomnia pipeline report to learn more about the emerging Hypersomnia therapies
Some of the key companies in the Hypersomnia Therapeutics Market include:
Key companies developing therapies for Hypersomnia are – Axsome Therapeutics, Alkermes, Zevra Therapeutics, Takeda, Aexon Labs, and others.
Hypersomnia Pipeline Analysis:
The Hypersomnia pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hypersomnia with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypersomnia Treatment.
Hypersomnia key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hypersomnia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypersomnia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hypersomnia drugs and therapies
Hypersomnia Pipeline Market Drivers
Increased Awareness and Diagnosis, Unmet Medical Need, Rising Prevalence, Advances in Neuroscience and Drug Development, Growing Investment in Research and Development (R&D), Supportive Regulatory Environment, are some of the important factors that are fueling the Hypersomnia Market.
Hypersomnia Pipeline Market Barriers
However, Lack of Clear Biomarkers, High Clinical Trial Costs, Regulatory Hurdles, Limited Patient Population, Efficacy and Safety Concerns, Market Competition, and other factors are creating obstacles in the Hypersomnia Market growth.
Scope of Hypersomnia Pipeline Drug Insight
Coverage: Global
Key Hypersomnia Companies: Avadel Pharmaceuticals, Zevra Therapeutics, Alkermes, and others
Key Hypersomnia Therapies: Lumryz, KP1077, ALKS 2680, and others
Hypersomnia Therapeutic Assessment: Hypersomnia current marketed and Hypersomnia emerging therapies
Hypersomnia Market Dynamics: Hypersomnia market drivers and Hypersomnia market barriers
Request for Sample PDF Report for Hypersomnia Pipeline Assessment and clinical trials
Table of Contents
1. Hypersomnia Report Introduction
2. Hypersomnia Executive Summary
3. Hypersomnia Overview
4. Hypersomnia- Analytical Perspective In-depth Commercial Assessment
5. Hypersomnia Pipeline Therapeutics
6. Hypersomnia Late Stage Products (Phase II/III)
7. Hypersomnia Mid Stage Products (Phase II)
8. Hypersomnia Early Stage Products (Phase I)
9. Hypersomnia Preclinical Stage Products
10. Hypersomnia Therapeutics Assessment
11. Hypersomnia Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypersomnia Key Companies
14. Hypersomnia Key Products
15. Hypersomnia Unmet Needs
16 . Hypersomnia Market Drivers and Barriers
17. Hypersomnia Future Perspectives and Conclusion
18. Hypersomnia Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/
